BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-62@catalystbrief.girapphe.com
DTSTAMP:20261117T061553Z
LAST-MODIFIED:20261117T061553Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Teva Branded Pharmaceutical Products R&D LLC — TEV-56248
  [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study to Test if a Fixed-Dose Com
 bination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preve
 nting Asthma Exacerbations.\nSource: https://clinicaltrials.gov/study/NCT0
 6052267\nhttps://catalystbrief.girapphe.com/e/62?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/62?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
